The University of Chicago Header Logo

Connection

Scott E. Eggener to Male

Back to Details
This is a "connection" page, showing publications Scott E. Eggener has written about Male.
Scott E. Eggener
Connection Strength
4.702
Male
  1. Time to stop reporting estimates of any prostate cancer risk with percentage of free prostate-specific antigen. Am J Clin Pathol. 2024 Jan 04; 161(1):1-3.
    View in: PubMed
    Score: 0.049
  2. The influence of the "cancer" label on perceptions and management decisions for low-grade prostate cancer. J Natl Cancer Inst. 2023 11 08; 115(11):1364-1373.
    View in: PubMed
    Score: 0.049
  3. Improving reader accuracy and specificity with the addition of hybrid multidimensional-MRI to multiparametric-MRI in diagnosing clinically significant prostate cancers. Abdom Radiol (NY). 2023 10; 48(10):3216-3228.
    View in: PubMed
    Score: 0.048
  4. Physician Perception of Grade Group 1 Prostate Cancer. Eur Urol Focus. 2023 11; 9(6):966-973.
    View in: PubMed
    Score: 0.047
  5. Risk Stratification of Low-risk Prostate Cancer: Individualizing Care in the Era of Active Surveillance. J Urol. 2023 07; 210(1):38-45.
    View in: PubMed
    Score: 0.047
  6. Focal Therapy for Prostate Cancer: Evolutionary Parallels to Breast Cancer Treatment. J Urol. 2023 01; 209(1):49-57.
    View in: PubMed
    Score: 0.045
  7. Blood Prostate-specific Antigen by Volume of Benign, Gleason Pattern 3 and 4 Prostate Tissue. Urology. 2022 12; 170:154-160.
    View in: PubMed
    Score: 0.045
  8. Low-Grade Prostate Cancer: Time to Stop Calling It Cancer. J Clin Oncol. 2022 09 20; 40(27):3110-3114.
    View in: PubMed
    Score: 0.044
  9. Radical Prostatectomy Without Biopsy: Audacious, Imprudent, or Innovative? Eur Urol. 2022 08; 82(2):161-162.
    View in: PubMed
    Score: 0.044
  10. Prostate Cancer, Decisional Regret and Exercise. J Urol. 2022 05; 207(5):952-953.
    View in: PubMed
    Score: 0.043
  11. Re: NCCN Prostate Cancer Guidelines Version 1.2022 - September 10, 2021. Eur Urol. 2022 02; 81(2):218.
    View in: PubMed
    Score: 0.043
  12. Active Surveillance: Very Much "Preferred" for Low-Risk Prostate Cancer. J Urol. 2022 02; 207(2):262-264.
    View in: PubMed
    Score: 0.043
  13. How Should Molecular Markers and Magnetic Resonance Imaging Be Used in the Early Detection of Prostate Cancer? Eur Urol Oncol. 2022 04; 5(2):135-137.
    View in: PubMed
    Score: 0.040
  14. Should Grade Group 1 (GG1) be called cancer? World J Urol. 2022 Jan; 40(1):15-19.
    View in: PubMed
    Score: 0.040
  15. Impact of Non-guideline-directed Care on Quality of Life in Testicular Cancer Survivors. Eur Urol Focus. 2021 Sep; 7(5):1137-1142.
    View in: PubMed
    Score: 0.040
  16. Prostate Cancer Outcomes Following Solid-Organ Transplantation: A SEER-Medicare Analysis. J Natl Cancer Inst. 2020 08 01; 112(8):847-854.
    View in: PubMed
    Score: 0.039
  17. Prostate-specific Antigen to Predict Early Success of Focal Therapy: Focusing on Appropriate Endpoints. Eur Urol. 2020 08; 78(2):161-162.
    View in: PubMed
    Score: 0.039
  18. Editorial Comment. J Urol. 2020 08; 204(2):287.
    View in: PubMed
    Score: 0.038
  19. National management trends in clinical stage IIA nonseminomatous germ cell tumor (NSGCT) and opportunities to avoid dual therapy. Urol Oncol. 2020 08; 38(8):687.e13-687.e18.
    View in: PubMed
    Score: 0.038
  20. Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline Summary. JCO Oncol Pract. 2020 06; 16(6):340-343.
    View in: PubMed
    Score: 0.038
  21. Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. J Clin Oncol. 2020 05 01; 38(13):1474-1494.
    View in: PubMed
    Score: 0.037
  22. Recognizing and minimizing bias: Helping patients make their best choice for prostate cancer management through multidisciplinary clinics. Cancer. 2020 02 01; 126(3):470-472.
    View in: PubMed
    Score: 0.037
  23. Editorial Comment. J Urol. 2019 11; 202(5):942-943.
    View in: PubMed
    Score: 0.037
  24. Editorial Comment. J Urol. 2019 08; 202(2):263.
    View in: PubMed
    Score: 0.036
  25. Lymph node count impacts survival following post-chemotherapy retroperitoneal lymphadenectomy for non-seminomatous testicular cancer: a population-based analysis. BJU Int. 2019 11; 124(5):792-800.
    View in: PubMed
    Score: 0.036
  26. Re: Use of Active Surveillance or Watchful Waiting for Low-risk Prostate Cancer and Management Trends Across Risk Groups in the United States 2010-2015. Eur Urol. 2019 08; 76(2):252.
    View in: PubMed
    Score: 0.036
  27. Editorial Comment. J Urol. 2019 02; 201(2):266-267.
    View in: PubMed
    Score: 0.035
  28. A 17-gene Panel for Prediction of Adverse Prostate Cancer Pathologic Features: Prospective Clinical Validation and Utility. Urology. 2019 04; 126:76-82.
    View in: PubMed
    Score: 0.035
  29. "Real-world" Practice Makes Perfect: Ensuring the Active Component of Active Surveillance for Prostate Cancer. Eur Urol. 2018 12; 74(6):708-709.
    View in: PubMed
    Score: 0.034
  30. Indications, evolving technique, and early outcomes with robotic retroperitoneal lymph node dissection. Curr Opin Urol. 2018 09; 28(5):461-468.
    View in: PubMed
    Score: 0.034
  31. Clinical and Radiographic Predictors of Great Vessel Resection or Reconstruction During Retroperitoneal Lymph Node Dissection for Testicular Cancer. Urology. 2019 01; 123:186-190.
    View in: PubMed
    Score: 0.034
  32. Late Relapse of Nonseminomatous Germ Cell Tumor 24 Years Later. Urology. 2018 Dec; 122:16-18.
    View in: PubMed
    Score: 0.034
  33. Incidence, Risk Factors, and Outcomes for Rectal Injury During Radical Prostatectomy: A Population-based Study. Eur Urol Oncol. 2018 12; 1(6):501-506.
    View in: PubMed
    Score: 0.034
  34. Novel focal therapy treatment options for prostate cancer. Curr Opin Urol. 2018 03; 28(2):178-183.
    View in: PubMed
    Score: 0.033
  35. Testicular Cancer: Epidemiology, Diagnosis, and Management. Med Clin North Am. 2018 Mar; 102(2):251-264.
    View in: PubMed
    Score: 0.032
  36. Nodal Metastases at Radical Prostatectomy: More Aggressive Disease Warrants Consideration of Multimodal Treatment. Eur Urol. 2018 06; 73(6):897-898.
    View in: PubMed
    Score: 0.032
  37. Prostate Cancer and the Evolving Role of Biomarkers in Screening and Diagnosis. Radiol Clin North Am. 2018 Mar; 56(2):187-196.
    View in: PubMed
    Score: 0.032
  38. Can Focal Treatment Replace Radical Treatment in Prostate Cancer? For Focal Therapy. Eur Urol Focus. 2017 12; 3(6):522-523.
    View in: PubMed
    Score: 0.032
  39. Minimal difference in survival between radical prostatectomy and observation in men with modest life expectancy. Evid Based Med. 2017 12; 22(6):222.
    View in: PubMed
    Score: 0.032
  40. Managing Cancer Relapse After Radical Prostatectomy: Adjuvant Versus Salvage Radiation Therapy. Urol Clin North Am. 2017 Nov; 44(4):597-609.
    View in: PubMed
    Score: 0.032
  41. In localised prostate cancer, radical prostatectomy was associated with more sexual dysfunction and urinary incontinence than radiation or active surveillance. Evid Based Med. 2017 10; 22(5):192.
    View in: PubMed
    Score: 0.032
  42. Contemporary management of men with high-risk localized prostate cancer in the United States. Prostate Cancer Prostatic Dis. 2017 09; 20(3):283-288.
    View in: PubMed
    Score: 0.031
  43. Impact of Perioperative Infection on Cancer Specific Survival after Nephrectomy for Renal Cell Carcinoma. J Urol. 2017 11; 198(5):1027-1032.
    View in: PubMed
    Score: 0.031
  44. AUA Policy Statement on the Use of Multiparametric Magnetic Resonance Imaging in the Diagnosis, Staging and Management of Prostate Cancer. J Urol. 2017 10; 198(4):832-838.
    View in: PubMed
    Score: 0.031
  45. Mildly elevated serum alpha-fetoprotein (AFP) among patients with testicular cancer may not be associated with residual cancer or need for treatment. Ann Oncol. 2017 04 01; 28(4):899-902.
    View in: PubMed
    Score: 0.031
  46. Prostate cancer detection following diagnosis of atypical small acinar proliferation. Can J Urol. 2017 Apr; 24(2):8714-8720.
    View in: PubMed
    Score: 0.031
  47. Influence of pathologist experience on positive surgical margins following radical prostatectomy. Urol Oncol. 2017 07; 35(7):461.e1-461.e6.
    View in: PubMed
    Score: 0.031
  48. Extraprostatic Extension Is Extremely Rare for Contemporary Gleason Score 6 Prostate Cancer. Eur Urol. 2017 09; 72(3):455-460.
    View in: PubMed
    Score: 0.030
  49. Risk of lymph node metastases in pathological gleason score=6 prostate adenocarcinoma: Analysis of institutional and population-based databases. Urol Oncol. 2017 01; 35(1):31.e1-31.e6.
    View in: PubMed
    Score: 0.030
  50. Adherence to National Comprehensive Cancer Network® Guidelines for Testicular Cancer. J Urol. 2017 03; 197(3 Pt 1):684-689.
    View in: PubMed
    Score: 0.030
  51. Management trends for men with early-stage nonseminomatous germ cell tumors of the testicle: An analysis of the National Cancer Database. Cancer. 2017 01 01; 123(2):245-252.
    View in: PubMed
    Score: 0.030
  52. Editorial Comment. J Urol. 2016 12; 196(6):1668-1669.
    View in: PubMed
    Score: 0.030
  53. Phase II Evaluation of Magnetic Resonance Imaging Guided Focal Laser Ablation of Prostate Cancer. J Urol. 2016 12; 196(6):1670-1675.
    View in: PubMed
    Score: 0.029
  54. The Impact of Perioperative Aspirin on Bleeding Complications Following Robotic Partial Nephrectomy. J Endourol. 2016 09; 30(9):997-1003.
    View in: PubMed
    Score: 0.029
  55. Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer. Eur Urol. 2017 03; 71(3):476-482.
    View in: PubMed
    Score: 0.029
  56. Patient-Initiated Prostate Cancer Screening Among Older U.S. Men. Ann Intern Med. 2016 05 17; 164(10):702-3.
    View in: PubMed
    Score: 0.029
  57. Comparison of Perioperative and Early Oncologic Outcomes between Open and Robotic Assisted Laparoscopic Prostatectomy in a Contemporary Population Based Cohort. J Urol. 2016 07; 196(1):76-81.
    View in: PubMed
    Score: 0.029
  58. National Economic Conditions and Patient Insurance Status Predict Prostate Cancer Diagnosis Rates and Management Decisions. J Urol. 2016 May; 195(5):1383-1389.
    View in: PubMed
    Score: 0.028
  59. Active surveillance monitoring: the role of novel biomarkers and imaging. Asian J Androl. 2015 Nov-Dec; 17(6):882-4; discussion 883.
    View in: PubMed
    Score: 0.028
  60. Clinically localized type 1 and 2 papillary renal cell carcinomas have similar survival outcomes following surgery. World J Urol. 2016 May; 34(5):687-93.
    View in: PubMed
    Score: 0.028
  61. Prostate Cancer Screening Biomarkers: An Emerging Embarrassment of 'Riches'? Eur Urol. 2016 07; 70(1):54-55.
    View in: PubMed
    Score: 0.028
  62. Prostate Cancer Screening. JAMA. 2015 Aug 25; 314(8):825-6.
    View in: PubMed
    Score: 0.028
  63. Contemporary Population-Based Comparison of Localized Ductal Adenocarcinoma and High-Risk Acinar Adenocarcinoma of the Prostate. Urology. 2015 Oct; 86(4):777-82.
    View in: PubMed
    Score: 0.027
  64. National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening. J Clin Oncol. 2015 Aug 01; 33(22):2416-23.
    View in: PubMed
    Score: 0.027
  65. Management of Low-Stage Testicular Seminoma. Urol Clin North Am. 2015 Aug; 42(3):287-98.
    View in: PubMed
    Score: 0.027
  66. Gleason 6 Prostate Cancer: Translating Biology into Population Health. J Urol. 2015 Sep; 194(3):626-34.
    View in: PubMed
    Score: 0.027
  67. Population-based analysis of salvage radical prostatectomy with examination of factors associated with adverse perioperative outcomes. Urol Oncol. 2015 Apr; 33(4):163.e1-6.
    View in: PubMed
    Score: 0.027
  68. How active should active surveillance be? BJU Int. 2015 Feb; 115(2):176-7.
    View in: PubMed
    Score: 0.027
  69. Population based analysis of incidence and predictors of open conversion during minimally invasive radical prostatectomy. J Urol. 2015 Mar; 193(3):826-31.
    View in: PubMed
    Score: 0.027
  70. Pathologic outcomes for low-risk prostate cancer after delayed radical prostatectomy in the United States. Urol Oncol. 2015 Apr; 33(4):164.e11-7.
    View in: PubMed
    Score: 0.027
  71. National trends in the management of low and intermediate risk prostate cancer in the United States. J Urol. 2015 Jan; 193(1):95-102.
    View in: PubMed
    Score: 0.026
  72. Commentary on "Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare." Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM, Department of Urology, New York University, New York, NY. J Urol 2013; 189(3):867-70. [Epub 2012 Oct 9]. doi: 10.1016/j.juro.2012.10.005. Urol Oncol. 2014 Aug; 32(6):935-6.
    View in: PubMed
    Score: 0.026
  73. Commentary on "Intermittent versus continuous androgen deprivation in prostate cancer." Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr, University of Michigan, Division of Hematology/Oncology, Ann Arbor, MI. N Engl J Med 2013; 368(14):1314-25. doi: 10.1056/NEJMoa1212299. Urol Oncol. 2014 Aug; 32(6):936-7.
    View in: PubMed
    Score: 0.026
  74. Commentary on "African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them?" Sundi D, Ross AE, Humphreys EB, Han M, Partin AW, Carter HB, Schaeffer EM, Johns Hopkins University, Baltimore, MD. J Clin Oncol 2013; 31(24):2991-7. [Epub 2013 Jun 17]. doi: 10.1200/JCO.2012.47.0302. Urol Oncol. 2014 Aug; 32(6):936.
    View in: PubMed
    Score: 0.026
  75. Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009. World J Urol. 2015 May; 33(5):623-31.
    View in: PubMed
    Score: 0.026
  76. Population-based analysis of treatment modalities and survival for clinically localized small-cell carcinoma of the prostate. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):286-91.
    View in: PubMed
    Score: 0.026
  77. Impact of warm versus cold ischemia on renal function following partial nephrectomy. World J Urol. 2015 Mar; 33(3):351-7.
    View in: PubMed
    Score: 0.025
  78. Laser ablation as focal therapy for prostate cancer. Curr Opin Urol. 2014 May; 24(3):236-40.
    View in: PubMed
    Score: 0.025
  79. Commentary on: "Long-term functional outcomes after treatment for localized prostate cancer." Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM, Van Horn RL, Penson DF. Department of Urologic Surgery and the Center for Surgical Quality and Outcomes Research, Vanderbilt University, Nashville, TN.: N Engl J Med 2013;368(5):436-45. doi: 10.1056/NEJMoa1209978. Urol Oncol. 2014 May; 32(4):513-4.
    View in: PubMed
    Score: 0.025
  80. Elastographic search for the (high-grade) tree in the (prostatic) forest. BJU Int. 2014 Apr; 113(4):514-5.
    View in: PubMed
    Score: 0.025
  81. Editorial comment. J Urol. 2014 Jul; 192(1):81.
    View in: PubMed
    Score: 0.025
  82. Ongoing Gleason grade migration in localized prostate cancer and implications for use of active surveillance. Eur Urol. 2014 Oct; 66(4):611-2.
    View in: PubMed
    Score: 0.025
  83. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making. Cancer. 2014 May 15; 120(10):1491-8.
    View in: PubMed
    Score: 0.025
  84. Critical evaluation of modified templates and current trends in retroperitoneal lymph node dissection. Curr Urol Rep. 2013 Oct; 14(5):511-7.
    View in: PubMed
    Score: 0.024
  85. Empiric antibiotics for an elevated prostate-specific antigen (PSA) level: a randomised, prospective, controlled multi-institutional trial. BJU Int. 2013 Nov; 112(7):925-9.
    View in: PubMed
    Score: 0.024
  86. The role of robot-assisted radical prostatectomy and pelvic lymph node dissection in the management of high-risk prostate cancer: a systematic review. Eur Urol. 2014 May; 65(5):918-27.
    View in: PubMed
    Score: 0.024
  87. MR imaging-guided focal laser ablation for prostate cancer: phase I trial. Radiology. 2013 Jun; 267(3):932-40.
    View in: PubMed
    Score: 0.023
  88. A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol. 2013 Jan; 189(1 Suppl):S19-25; discussion S25.
    View in: PubMed
    Score: 0.023
  89. Re: Active surveillance failure for prostate cancer: does the delay in treatment increase the risk of urinary incontinence? Can J Urol. 2012 Jun; 19(3):6292.
    View in: PubMed
    Score: 0.022
  90. 2008 US Preventive Services Task Force recommendations and prostate cancer screening rates. JAMA. 2012 Apr 25; 307(16):1692-4.
    View in: PubMed
    Score: 0.022
  91. The association of the human development index with global kidney cancer incidence and mortality. J Urol. 2012 Jun; 187(6):1978-83.
    View in: PubMed
    Score: 0.022
  92. Environmental toxicology of testicular cancer. Urol Oncol. 2012 Mar-Apr; 30(2):212-5.
    View in: PubMed
    Score: 0.022
  93. Hazard of prostate cancer specific mortality after radical prostatectomy. J Urol. 2012 Jan; 187(1):124-7.
    View in: PubMed
    Score: 0.021
  94. Cause-specific mortality following radical prostatectomy. Prostate Cancer Prostatic Dis. 2012 Mar; 15(1):106-10.
    View in: PubMed
    Score: 0.021
  95. Focal therapy for clinically localized prostate cancer. Arch Esp Urol. 2011 Oct; 64(8):815-22.
    View in: PubMed
    Score: 0.021
  96. Global trends in testicular cancer incidence and mortality. Eur Urol. 2011 Aug; 60(2):374-9.
    View in: PubMed
    Score: 0.021
  97. Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. J Clin Oncol. 2011 May 01; 29(13):1736-43.
    View in: PubMed
    Score: 0.020
  98. Editorial comment. J Urol. 2011 Apr; 185(4):1254-5.
    View in: PubMed
    Score: 0.020
  99. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol. 2011 Mar; 185(3):869-75.
    View in: PubMed
    Score: 0.020
  100. Chronic kidney disease before and after partial nephrectomy. J Urol. 2011 Jan; 185(1):43-8.
    View in: PubMed
    Score: 0.020
  101. Chronic Kidney Disease Epidemiology Collaboration versus Modification of Diet in Renal Disease equations for renal function evaluation in patients undergoing partial nephrectomy. J Urol. 2010 Nov; 184(5):1867-71.
    View in: PubMed
    Score: 0.020
  102. Focal therapy for prostate cancer: possibilities and limitations. Eur Urol. 2010 Jul; 58(1):57-64.
    View in: PubMed
    Score: 0.019
  103. Regarding: 'High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series'. Br J Cancer. 2009 Dec 15; 101(12):2057-8; author reply 2059.
    View in: PubMed
    Score: 0.019
  104. Retroperitoneal lymph node dissection: reassessment of modified templates. BJU Int. 2009 Nov; 104(9 Pt B):1369-75.
    View in: PubMed
    Score: 0.018
  105. Active surveillance for low-risk localized prostate cancer. Oncology (Williston Park). 2009 Oct; 23(11):974-9.
    View in: PubMed
    Score: 0.018
  106. Re: Effectiveness of antibiotics given to asymptomatic men for an increased prostate specific antigen. S. Baltaci, E. Suer, A. H. Haliloglu, M. I. Gokce, A. H. Elhan and Y. Beduk. J Urol 2009; 181: 128-132. J Urol. 2009 Jul; 182(1):396-7.
    View in: PubMed
    Score: 0.018
  107. Length of positive surgical margin after radical prostatectomy as a predictor of biochemical recurrence. J Urol. 2009 Jul; 182(1):139-44.
    View in: PubMed
    Score: 0.018
  108. Patient selection for focal therapy of localized prostate cancer. Curr Opin Urol. 2009 May; 19(3):268-73.
    View in: PubMed
    Score: 0.018
  109. The evolution, controversies, and potential pitfalls of modified retroperitoneal lymph node dissection templates. World J Urol. 2009 Aug; 27(4):477-83.
    View in: PubMed
    Score: 0.018
  110. The clinical diversity of postchemotherapy germ cell teratoma. Cancer. 2009 Mar 15; 115(6):1138-41.
    View in: PubMed
    Score: 0.018
  111. A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol. 2009 Apr; 181(4):1635-41; discussion 1641.
    View in: PubMed
    Score: 0.018
  112. Editorial comment on: Pharmacological approaches to reducing the risk of prostate cancer. Eur Urol. 2009 May; 55(5):1073-4.
    View in: PubMed
    Score: 0.018
  113. Editorial comment on: Preservation of lateral prostatic fascia is associated with urine continence after robotic-assisted prostatectomy. Eur Urol. 2009 Apr; 55(4):900-1.
    View in: PubMed
    Score: 0.018
  114. Comparison of models to predict clinical failure after radical prostatectomy. Cancer. 2009 Jan 15; 115(2):303-10.
    View in: PubMed
    Score: 0.017
  115. Editorial comment on: Reducing laparoscopic radical prostatectomy false-positive margin rates using cyanoacrylate tissue glue. Eur Urol. 2009 Oct; 56(4):658.
    View in: PubMed
    Score: 0.017
  116. Focal treatment of prostate cancer with vascular-targeted photodynamic therapy. ScientificWorldJournal. 2008 Oct 03; 8:963-73.
    View in: PubMed
    Score: 0.017
  117. Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. J Urol. 2008 Sep; 180(3):873-8; discussion 878.
    View in: PubMed
    Score: 0.017
  118. Editorial comment on: Analysis of T1c prostate cancers treated at very low prostate-specific antigen levels. Eur Urol. 2009 Mar; 55(3):616.
    View in: PubMed
    Score: 0.017
  119. Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program. Urology. 2008 Jun; 71(6):1016-9.
    View in: PubMed
    Score: 0.017
  120. Laparoscopic radical prostatectomy: ten years later, time for evidence-based foundation. Eur Urol. 2008 Jul; 54(1):4-7.
    View in: PubMed
    Score: 0.016
  121. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol. 2007 Dec; 178(6):2260-7.
    View in: PubMed
    Score: 0.016
  122. Editorial comment on: Methods of calculating prostate-specific antigen velocity. Eur Urol. 2007 Oct; 52(4):1050-1.
    View in: PubMed
    Score: 0.016
  123. Radical prostatectomy shortly after prostate biopsy does not affect operative difficulty or efficacy. Urology. 2007 Jun; 69(6):1128-33.
    View in: PubMed
    Score: 0.016
  124. Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer. J Urol. 2007 Mar; 177(3):937-42; discussion 942-3.
    View in: PubMed
    Score: 0.015
  125. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors. Cancer. 2007 Feb 01; 109(3):528-35.
    View in: PubMed
    Score: 0.015
  126. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy. J Urol. 2006 Oct; 176(4 Pt 1):1399-403.
    View in: PubMed
    Score: 0.015
  127. Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol. 2006 Jul 01; 24(19):3101-6.
    View in: PubMed
    Score: 0.015
  128. Enhancement of intermittent androgen ablation by "off-cycle" maintenance with finasteride in LNCaP prostate cancer xenograft model. Prostate. 2006 Apr 01; 66(5):495-502.
    View in: PubMed
    Score: 0.014
  129. Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy. J Urol. 2005 Aug; 174(2):500-4.
    View in: PubMed
    Score: 0.014
  130. Magnetic resonance angiography for the nonpalpable testis: a cost and cancer risk analysis. J Urol. 2005 May; 173(5):1745-9; discussion 1749-50.
    View in: PubMed
    Score: 0.014
  131. Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy. J Urol. 2005 Apr; 173(4):1150-5.
    View in: PubMed
    Score: 0.013
  132. Bilateral pulmonary artery tumour emboli from renal carcinoma. Lancet Oncol. 2004 Mar; 5(3):173.
    View in: PubMed
    Score: 0.012
  133. Granulocytic sarcoma of the testis. Urology. 2004 Mar; 63(3):584-5.
    View in: PubMed
    Score: 0.012
  134. PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19). J Clin Oncol. 2024 Apr 01; 42(10):1114-1123.
    View in: PubMed
    Score: 0.012
  135. Renal tumors in young adults. J Urol. 2004 Jan; 171(1):106-10.
    View in: PubMed
    Score: 0.012
  136. Urolithiasis associated with topiramate. Int Braz J Urol. 2004 Jan-Feb; 30(1):29-30; discussion 30-1.
    View in: PubMed
    Score: 0.012
  137. Penile refracture: case report. J Trauma. 2003 Oct; 55(4):793-4.
    View in: PubMed
    Score: 0.012
  138. Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer. J Clin Oncol. 2023 Dec 01; 41(34):5296-5305.
    View in: PubMed
    Score: 0.012
  139. Free PSA and Clinically Significant and Fatal Prostate Cancer in the PLCO Screening Trial. J Urol. 2023 10; 210(4):630-638.
    View in: PubMed
    Score: 0.012
  140. Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy. J Urol. 2023 07; 210(1):54-63.
    View in: PubMed
    Score: 0.012
  141. Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. J Urol. 2023 07; 210(1):46-53.
    View in: PubMed
    Score: 0.012
  142. Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy. J Clin Oncol. 2023 06 01; 41(16):3009-3018.
    View in: PubMed
    Score: 0.012
  143. Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study. Eur J Cancer. 2023 03; 182:144-154.
    View in: PubMed
    Score: 0.012
  144. Robotic post-chemotherapy retroperitoneal lymph node dissection for testicular cancer: A multicenter collaborative study. Urol Oncol. 2023 02; 41(2):111.e7-111.e14.
    View in: PubMed
    Score: 0.011
  145. A population-based evaluation of tunica vaginalis mesothelioma: An analysis of the National Cancer Database. Urol Oncol. 2023 01; 41(1):52.e11-52.e20.
    View in: PubMed
    Score: 0.011
  146. Assessing the accuracy of multiparametric MRI to predict clinically significant prostate cancer in biopsy naïve men across racial/ethnic groups. BMC Urol. 2022 Jul 18; 22(1):107.
    View in: PubMed
    Score: 0.011
  147. Systematic review of the impact of a plant-based diet on prostate cancer incidence and outcomes. Prostate Cancer Prostatic Dis. 2022 09; 25(3):444-452.
    View in: PubMed
    Score: 0.011
  148. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. Part III: Principles of Radiation and Future Directions. J Urol. 2022 07; 208(1):26-33.
    View in: PubMed
    Score: 0.011
  149. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management. J Urol. 2022 07; 208(1):10-18.
    View in: PubMed
    Score: 0.011
  150. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up. J Urol. 2022 07; 208(1):19-25.
    View in: PubMed
    Score: 0.011
  151. Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. Eur Urol. 2022 10; 82(4):341-351.
    View in: PubMed
    Score: 0.011
  152. Minimally invasive retroperitoneal lymph node dissection for men with testis cancer: a retrospective cohort study of safety and feasibility. World J Urol. 2022 Jun; 40(6):1505-1512.
    View in: PubMed
    Score: 0.011
  153. Hematuria following Post-Prostatectomy Radiotherapy: Incidence Increases with Long-Term Followup. J Urol. 2022 06; 207(6):1236-1245.
    View in: PubMed
    Score: 0.011
  154. Clinical and pathological features of renal epithelioid angiomyolipoma (PEComa): A single institution series. Urol Oncol. 2022 02; 40(2):18-24.
    View in: PubMed
    Score: 0.011
  155. Validation of Prostate Tissue Composition by Using Hybrid Multidimensional MRI: Correlation with Histologic Findings. Radiology. 2022 02; 302(2):368-377.
    View in: PubMed
    Score: 0.011
  156. Bladder lipoma. J Urol. 2001 Oct; 166(4):1395.
    View in: PubMed
    Score: 0.011
  157. Pathological characteristics of the large renal mass: potential implication for clinical role of renal biopsy. Can J Urol. 2021 04; 28(2):10620-10624.
    View in: PubMed
    Score: 0.010
  158. Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis. Eur Urol. 2021 03; 79(3):419-426.
    View in: PubMed
    Score: 0.010
  159. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer. J Urol. 2021 Mar; 205(3):769-779.
    View in: PubMed
    Score: 0.010
  160. T2*-weighted MRI as a non-contrast-enhanced method for assessment of focal laser ablation zone extent in prostate cancer thermotherapy. Eur Radiol. 2021 Jan; 31(1):325-332.
    View in: PubMed
    Score: 0.010
  161. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol. 2020 08 20; 38(24):2798-2811.
    View in: PubMed
    Score: 0.010
  162. Update of the Standard Operating Procedure on the Use of Multiparametric Magnetic Resonance Imaging for the Diagnosis, Staging and Management of Prostate Cancer. J Urol. 2020 Apr; 203(4):706-712.
    View in: PubMed
    Score: 0.009
  163. SPARED Collaboration: Patient Selection for Partial Gland Ablation in Men with Localized Prostate Cancer. J Urol. 2019 11; 202(5):952-958.
    View in: PubMed
    Score: 0.009
  164. Reply by Authors. J Urol. 2019 11; 202(5):958.
    View in: PubMed
    Score: 0.009
  165. Recurrence After Robotic Retroperitoneal Lymph Node Dissection Raises More Questions than Answers. Eur Urol. 2019 11; 76(5):610-611.
    View in: PubMed
    Score: 0.009
  166. Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public Workshop. J Urol. 2020 01; 203(1):115-119.
    View in: PubMed
    Score: 0.009
  167. Impact of preoperative prostate magnetic resonance imaging on the surgical management of high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2020 03; 23(1):172-178.
    View in: PubMed
    Score: 0.009
  168. Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline. J Urol. 2019 08; 202(2):272-281.
    View in: PubMed
    Score: 0.009
  169. Nationwide Patterns of Care for Stage II Nonseminomatous Germ Cell Tumor of the Testicle. Eur Urol Oncol. 2020 04; 3(2):198-206.
    View in: PubMed
    Score: 0.009
  170. The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement. Eur Urol. 2019 Sep; 76(3):268-272.
    View in: PubMed
    Score: 0.009
  171. Patient-reported Outcomes and Late Toxicity After Postprostatectomy Intensity-modulated Radiation Therapy. Eur Urol. 2019 11; 76(5):686-692.
    View in: PubMed
    Score: 0.009
  172. Metastatic prostate cancer at diagnosis and through progression in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer. 2019 09 01; 125(17):2965-2974.
    View in: PubMed
    Score: 0.009
  173. Diagnosis of Prostate Cancer by Use of MRI-Derived Quantitative Risk Maps: A Feasibility Study. AJR Am J Roentgenol. 2019 08; 213(2):W66-W75.
    View in: PubMed
    Score: 0.009
  174. International and Multi-institutional Assessment of Factors Associated With Performance and Quality of Lymph Node Dissection During Radical Nephrectomy. Urology. 2019 Jul; 129:132-138.
    View in: PubMed
    Score: 0.009
  175. Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project. World J Urol. 2019 Oct; 37(10):2147-2153.
    View in: PubMed
    Score: 0.009
  176. Multi-institutional Clinical Tool for Predicting High-risk Lesions on 3Tesla Multiparametric Prostate Magnetic Resonance Imaging. Eur Urol Oncol. 2019 05; 2(3):257-264.
    View in: PubMed
    Score: 0.009
  177. Comparison of T2-Weighted Imaging, DWI, and Dynamic Contrast-Enhanced MRI for Calculation of Prostate Cancer Index Lesion Volume: Correlation With Whole-Mount Pathology. AJR Am J Roentgenol. 2019 02; 212(2):351-356.
    View in: PubMed
    Score: 0.009
  178. Evaluation of tumor coverage after MR-guided prostate focal laser ablation therapy. Med Phys. 2019 Feb; 46(2):800-810.
    View in: PubMed
    Score: 0.009
  179. Region-specific microRNA signatures in the human epididymis. Asian J Androl. 2018 Nov-Dec; 20(6):539-544.
    View in: PubMed
    Score: 0.009
  180. Evaluation of Focal Laser Ablation of Prostate Cancer Using High Spectral and Spatial Resolution Imaging: A Pilot Study. J Magn Reson Imaging. 2019 05; 49(5):1374-1380.
    View in: PubMed
    Score: 0.009
  181. Feasibility of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Using Low-Dose Gadolinium: Comparative Performance With Standard Dose in Prostate Cancer Diagnosis. Invest Radiol. 2018 10; 53(10):609-615.
    View in: PubMed
    Score: 0.009
  182. A novel transcriptional network for the androgen receptor in human epididymis epithelial cells. Mol Hum Reprod. 2018 09 01; 24(9):433-443.
    View in: PubMed
    Score: 0.009
  183. MRI Findings After MRI-Guided Focal Laser Ablation of Prostate Cancer. AJR Am J Roentgenol. 2018 09; 211(3):595-604.
    View in: PubMed
    Score: 0.008
  184. Ablation energies for focal treatment of prostate cancer. World J Urol. 2019 Mar; 37(3):409-418.
    View in: PubMed
    Score: 0.008
  185. Predominantly cystic clear cell renal cell carcinoma and multilocular cystic renal neoplasm of low malignant potential form a low-grade spectrum. Virchows Arch. 2018 Jul; 473(1):85-93.
    View in: PubMed
    Score: 0.008
  186. No Effect of Music on Anxiety and Pain During Transrectal Prostate Biopsies: A Randomized Trial. Urology. 2018 Jul; 117:31-35.
    View in: PubMed
    Score: 0.008
  187. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018 May 10; 378(19):1767-1777.
    View in: PubMed
    Score: 0.008
  188. Region-specific innate antiviral responses of the human epididymis. Mol Cell Endocrinol. 2018 09 15; 473:72-78.
    View in: PubMed
    Score: 0.008
  189. Contemporary Incidence and Outcomes of Prostate Cancer Lymph Node Metastases. J Urol. 2018 06; 199(6):1510-1517.
    View in: PubMed
    Score: 0.008
  190. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol. 2018 02 01; 36(4):414-424.
    View in: PubMed
    Score: 0.008
  191. Nerve Bundle Hydrodissection and Sexual Function after Robot Prostatectomy. JSLS. 2017 Oct-Dec; 21(4).
    View in: PubMed
    Score: 0.008
  192. African-American Prostate Cancer Disparities. Curr Urol Rep. 2017 Aug 14; 18(10):81.
    View in: PubMed
    Score: 0.008
  193. Low-risk Prostate Cancer: Identification, Management, and Outcomes. Eur Urol. 2017 08; 72(2):238-249.
    View in: PubMed
    Score: 0.008
  194. Variability in Outcomes for Patients with Intermediate-risk Prostate Cancer (Gleason Score 7, International Society of Urological Pathology Gleason Group 2-3) and Implications for Risk Stratification: A Systematic Review. Eur Urol Focus. 2017 10; 3(4-5):487-497.
    View in: PubMed
    Score: 0.008
  195. Commentary regarding a recent collaborative consensus statement addressing prostate MRI and MRI-targeted biopsy in patients with a prior negative prostate biopsy. Abdom Radiol (NY). 2017 Feb; 42(2):346-349.
    View in: PubMed
    Score: 0.008
  196. Prognostic Significance of Percentage and Architectural Types of Contemporary Gleason Pattern 4 Prostate Cancer in Radical Prostatectomy. Am J Surg Pathol. 2016 10; 40(10):1400-6.
    View in: PubMed
    Score: 0.007
  197. New and Established Technology in Focal Ablation of the Prostate: A Systematic Review. Eur Urol. 2017 01; 71(1):17-34.
    View in: PubMed
    Score: 0.007
  198. Increasing incidence of metastatic prostate cancer in the United States (2004-2013). Prostate Cancer Prostatic Dis. 2016 12; 19(4):395-397.
    View in: PubMed
    Score: 0.007
  199. Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR. J Urol. 2016 12; 196(6):1613-1618.
    View in: PubMed
    Score: 0.007
  200. Standardization of definitions in focal therapy of prostate cancer: report from a Delphi consensus project. World J Urol. 2016 Oct; 34(10):1373-82.
    View in: PubMed
    Score: 0.007
  201. HNF1 regulates critical processes in the human epididymis epithelium. Mol Cell Endocrinol. 2016 Apr 15; 425:94-102.
    View in: PubMed
    Score: 0.007
  202. Bladder dose-volume parameters are associated with urinary incontinence after postoperative intensity modulated radiation therapy for prostate cancer. Pract Radiat Oncol. 2016 Sep-Oct; 6(5):e179-e185.
    View in: PubMed
    Score: 0.007
  203. The challenging landscape of medical device approval in localized prostate cancer. Nat Rev Urol. 2016 Feb; 13(2):91-8.
    View in: PubMed
    Score: 0.007
  204. Expression profiles of human epididymis epithelial cells reveal the functional diversity of caput, corpus and cauda regions. Mol Hum Reprod. 2016 Feb; 22(2):69-82.
    View in: PubMed
    Score: 0.007
  205. Prediction of renal mass aggressiveness using clinical and radiographic features: a global, multicentre prospective study. BJU Int. 2016 06; 117(6):914-22.
    View in: PubMed
    Score: 0.007
  206. Giant Multilocular Cystadenoma of the Prostate. Radiographics. 2015 Jul-Aug; 35(4):1051-5.
    View in: PubMed
    Score: 0.007
  207. The impact of days off between cases on perioperative outcomes for robotic-assisted laparoscopic prostatectomy. World J Urol. 2016 Feb; 34(2):269-74.
    View in: PubMed
    Score: 0.007
  208. Corneal abrasion in hysterectomy and prostatectomy: role of laparoscopic and robotic assistance. Anesthesiology. 2015 May; 122(5):994-1001.
    View in: PubMed
    Score: 0.007
  209. Genomic Predictors of Outcome in Prostate Cancer. Eur Urol. 2015 Dec; 68(6):1033-44.
    View in: PubMed
    Score: 0.007
  210. Robotic-assisted pelvic lymph node dissection for prostate cancer: frequency of nodal metastases and oncological outcomes. World J Urol. 2015 Nov; 33(11):1689-94.
    View in: PubMed
    Score: 0.007
  211. Characterization of primary cultures of adult human epididymis epithelial cells. Fertil Steril. 2015 Mar; 103(3):647-54.e1.
    View in: PubMed
    Score: 0.007
  212. Preoperative nuclear renal scan underestimates renal function after radical nephrectomy. Urology. 2014 Dec; 84(6):1402-6.
    View in: PubMed
    Score: 0.007
  213. Focal therapy: patients, interventions, and outcomes--a report from a consensus meeting. Eur Urol. 2015 Apr; 67(4):771-7.
    View in: PubMed
    Score: 0.006
  214. The impact of body mass index on renal functional outcomes following minimally invasive partial nephrectomy. J Endourol. 2014 Nov; 28(11):1338-44.
    View in: PubMed
    Score: 0.006
  215. Metastatic small cell carcinoma of the prostate: Population-based analysis of patient characteristics and treatment paradigms. Urol Oncol. 2015 Feb; 33(2):70.e1-7.
    View in: PubMed
    Score: 0.006
  216. Population-based assessment of prostate-specific antigen testing for prostate cancer in the elderly. Urol Oncol. 2015 Feb; 33(2):69.e29-34.
    View in: PubMed
    Score: 0.006
  217. Effect of depression on diagnosis, treatment, and mortality of men with clinically localized prostate cancer. J Clin Oncol. 2014 Aug 10; 32(23):2471-8.
    View in: PubMed
    Score: 0.006
  218. Health technology assessment in evolution - focal therapy in localised prostate cancer. Expert Rev Anticancer Ther. 2014 Nov; 14(11):1359-67.
    View in: PubMed
    Score: 0.006
  219. Use of social media in urology: data from the American Urological Association (AUA). BJU Int. 2014 Jun; 113(6):993-8.
    View in: PubMed
    Score: 0.006
  220. Dynamic contrast-enhanced MR imaging features of the normal central zone of the prostate. Acad Radiol. 2014 May; 21(5):569-77.
    View in: PubMed
    Score: 0.006
  221. Apparent diffusion coefficient for prostate cancer imaging: impact of B values. AJR Am J Roentgenol. 2014 Mar; 202(3):W247-53.
    View in: PubMed
    Score: 0.006
  222. Validation of quantitative analysis of multiparametric prostate MR images for prostate cancer detection and aggressiveness assessment: a cross-imager study. Radiology. 2014 May; 271(2):461-71.
    View in: PubMed
    Score: 0.006
  223. Focal therapy in prostate cancer: international multidisciplinary consensus on trial design. Eur Urol. 2014 Jun; 65(6):1078-83.
    View in: PubMed
    Score: 0.006
  224. The volume of nonneoplastic parenchyma in a minimally invasive partial nephrectomy specimen: predictive factors and impact on renal function. J Endourol. 2014 Feb; 28(2):196-200.
    View in: PubMed
    Score: 0.006
  225. Prostate volumes derived from MRI and volume-adjusted serum prostate-specific antigen: correlation with Gleason score of prostate cancer. AJR Am J Roentgenol. 2013 Nov; 201(5):1041-8.
    View in: PubMed
    Score: 0.006
  226. Revisiting the central gland anatomy via MRI: does the central gland extend below the level of verumontanum? J Magn Reson Imaging. 2014 Jan; 39(1):167-71.
    View in: PubMed
    Score: 0.006
  227. Early discharge after laparoscopic or robotic partial nephrectomy: care pathway evaluation. BJU Int. 2014 Apr; 113(4):592-7.
    View in: PubMed
    Score: 0.006
  228. Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer. Cancer. 2013 Nov 15; 119(22):3992-4002.
    View in: PubMed
    Score: 0.006
  229. Do margins matter? The influence of positive surgical margins on prostate cancer-specific mortality. Eur Urol. 2014 Apr; 65(4):675-80.
    View in: PubMed
    Score: 0.006
  230. Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol. 2013 Oct; 64(4):544-52.
    View in: PubMed
    Score: 0.006
  231. Seminal vesicle invasion in prostate cancer: evaluation by using multiparametric endorectal MR imaging. Radiology. 2013 Jun; 267(3):797-806.
    View in: PubMed
    Score: 0.006
  232. Quantitative analysis of multiparametric prostate MR images: differentiation between prostate cancer and normal tissue and correlation with Gleason score--a computer-aided diagnosis development study. Radiology. 2013 Jun; 267(3):787-96.
    View in: PubMed
    Score: 0.006
  233. Differential use of partial nephrectomy for intermediate and high complexity tumors may explain variability in reported utilization rates. J Urol. 2013 Jun; 189(6):2047-53.
    View in: PubMed
    Score: 0.006
  234. Short (= 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy. BJU Int. 2013 Apr; 111(4):559-63.
    View in: PubMed
    Score: 0.006
  235. Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2013 Feb 01; 85(2):378-84.
    View in: PubMed
    Score: 0.006
  236. Imaging-guided prostate biopsy: conventional and emerging techniques. Radiographics. 2012 May-Jun; 32(3):819-37.
    View in: PubMed
    Score: 0.005
  237. Role of transrectal ultrasonography (TRUS) in focal therapy of prostate cancer: report from a Consensus Panel. BJU Int. 2012 Oct; 110(7):942-8.
    View in: PubMed
    Score: 0.005
  238. Local staging of prostate cancer with MRI. Diagn Interv Radiol. 2012 Jul-Aug; 18(4):365-73.
    View in: PubMed
    Score: 0.005
  239. High-grade ureteroscopic biopsy is associated with advanced pathology of upper-tract urothelial carcinoma tumors at definitive surgical resection. J Endourol. 2012 Apr; 26(4):398-402.
    View in: PubMed
    Score: 0.005
  240. Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. AJR Am J Roentgenol. 2011 Dec; 197(6):1382-90.
    View in: PubMed
    Score: 0.005
  241. High-resolution MRI of excised human prostate specimens acquired with 9.4T in detection and identification of cancers: validation of a technique. J Magn Reson Imaging. 2011 Oct; 34(4):956-61.
    View in: PubMed
    Score: 0.005
  242. Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma. Urol Oncol. 2013 Aug; 31(6):904-8.
    View in: PubMed
    Score: 0.005
  243. Clinical and histologic predictors of renal function decline after laparoscopic partial nephrectomy. J Endourol. 2011 Sep; 25(9):1435-41.
    View in: PubMed
    Score: 0.005
  244. Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int. 2011 Sep; 108(5):701-5.
    View in: PubMed
    Score: 0.005
  245. Gleason 6 prostate cancer in one or two biopsy cores can harbor more aggressive disease. J Endourol. 2011 Apr; 25(4):699-703.
    View in: PubMed
    Score: 0.005
  246. Histopathological predictors of renal function decrease after laparoscopic radical nephrectomy. J Urol. 2010 Nov; 184(5):1872-6.
    View in: PubMed
    Score: 0.005
  247. Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J Urol. 2010 Jul; 184(1):69-73.
    View in: PubMed
    Score: 0.005
  248. Impact of ischemia on renal function after laparoscopic partial nephrectomy: a multicenter study. J Urol. 2010 May; 183(5):1714-8.
    View in: PubMed
    Score: 0.005
  249. The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer. Urology. 2010 Jun; 75(6):1431-5.
    View in: PubMed
    Score: 0.005
  250. Laparoscopic partial nephrectomy: a single-center evolving experience. Urology. 2010 Feb; 75(2):282-7.
    View in: PubMed
    Score: 0.005
  251. Laparoscopic partial nephrectomy: predictors of prolonged warm ischemia. J Urol. 2009 Sep; 182(3):860-5.
    View in: PubMed
    Score: 0.005
  252. Suppressive roles of calreticulin in prostate cancer growth and metastasis. Am J Pathol. 2009 Aug; 175(2):882-90.
    View in: PubMed
    Score: 0.005
  253. Robotic radical prostatectomy in overweight and obese patients: oncological and validated-functional outcomes. Urology. 2009 Feb; 73(2):316-22.
    View in: PubMed
    Score: 0.004
  254. Clinical outcome and predictors of survival in late relapse of germ cell tumor. J Clin Oncol. 2008 Dec 01; 26(34):5524-9.
    View in: PubMed
    Score: 0.004
  255. A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy--can we predict adverse pathological outcomes? J Urol. 2008 Dec; 180(6):2436-40.
    View in: PubMed
    Score: 0.004
  256. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol. 2008 Nov; 180(5):1964-7; discussion 1967-8.
    View in: PubMed
    Score: 0.004
  257. Survival rates after resection for localized kidney cancer: 1989 to 2004. Cancer. 2008 Jul 01; 113(1):84-96.
    View in: PubMed
    Score: 0.004
  258. Positive surgical margins at partial nephrectomy: predictors and oncological outcomes. J Urol. 2008 Jun; 179(6):2158-63.
    View in: PubMed
    Score: 0.004
  259. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell. 2008 Jun; 13(6):519-28.
    View in: PubMed
    Score: 0.004
  260. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol. 2008 May; 53(5):950-9.
    View in: PubMed
    Score: 0.004
  261. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol. 2007 Oct 01; 25(28):4365-9.
    View in: PubMed
    Score: 0.004
  262. Expression and function of the human androgen-responsive gene ADI1 in prostate cancer. Neoplasia. 2007 Aug; 9(8):643-51.
    View in: PubMed
    Score: 0.004
  263. Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. Clin Cancer Res. 2007 Jul 15; 13(14):4130-8.
    View in: PubMed
    Score: 0.004
  264. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol. 2007 Aug; 178(2):493-9; discussion 499.
    View in: PubMed
    Score: 0.004
  265. Perioperative clinical thromboembolic events after radical or partial nephrectomy. Urology. 2006 Nov; 68(5):988-92.
    View in: PubMed
    Score: 0.004
  266. Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results. Urol Oncol. 2006 Nov-Dec; 24(6):465-71.
    View in: PubMed
    Score: 0.004
  267. The natural history of noncastrate metastatic prostate cancer after radical prostatectomy. Eur Urol. 2007 Apr; 51(4):940-7; discussion 947-8.
    View in: PubMed
    Score: 0.004
  268. Temporary renal ischemia during nephron sparing surgery is associated with short-term but not long-term impairment in renal function. J Urol. 2006 Oct; 176(4 Pt 1):1339-43; discussion 1343.
    View in: PubMed
    Score: 0.004
  269. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients. J Urol. 2006 Aug; 176(2):482-5.
    View in: PubMed
    Score: 0.004
  270. Use of 2.6 ng/ml prostate specific antigen prompt for biopsy in men older than 60 years. J Urol. 2005 Dec; 174(6):2154-7, discussion 2157.
    View in: PubMed
    Score: 0.004
  271. Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease. Urology. 2005 Jul; 66(1):156-60.
    View in: PubMed
    Score: 0.003
  272. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin Cancer Res. 2005 Jul 01; 11(13):4905-11.
    View in: PubMed
    Score: 0.003
  273. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol. 2004 Dec; 172(6 Pt 1):2227-31.
    View in: PubMed
    Score: 0.003
  274. Plasma cell infiltration of the urinary bladder. Urology. 2004 Jul; 64(1):156-7.
    View in: PubMed
    Score: 0.003
  275. The etiology of urolithiasis in HIV infected patients. J Urol. 2003 Feb; 169(2):475-7.
    View in: PubMed
    Score: 0.003
  276. Long-term survival after "drop metastases" of renal cell carcinoma to the bladder. Urology. 2002 Oct; 60(4):697.
    View in: PubMed
    Score: 0.003
  277. Irritative voiding symptoms and microscopic hematuria caused by intraperitoneal calcified fat necrosis. Urology. 2002 Mar; 59(3):444.
    View in: PubMed
    Score: 0.003
  278. Anatomy of the rectourethralis muscle. Eur Urol. 2002 Jan; 41(1):94-100.
    View in: PubMed
    Score: 0.003
  279. Nitric oxide contributes to the rise in forearm blood flow during mental stress in humans. J Physiol. 1994 Oct 15; 480 ( Pt 2):361-8.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.